- Published on
Ophthalmology – Primary Optic Nerve Sheath Meningioma
Basics
Description
Optic nerve sheath meningioma (ONSM) is a usually benign, slow-growing meningioma arising from the arachnoid cap cells of the meninges surrounding the optic nerve.
It produces a chronic compressive optic neuropathy through:
- Direct compression of the optic nerve
- Compromise of the pial vascular supply
- Compression of the central retinal venous circulation
The classic clinical pattern is:
Slowly progressive, painless, unilateral visual loss in a middle-aged adult
with characteristic enhancement around the optic nerve on orbital imaging.
Primary vs Secondary ONSM
Primary ONSM
Arises directly from the:
- Intraorbital optic nerve sheath
- Optic canalicular sheath
This is the classic form.
Secondary Optic Nerve Sheath Involvement
A meningioma arising elsewhere, particularly:
- Planum sphenoidale
- Tuberculum sellae
- Sphenoid wing
may secondarily extend along or compress the optic nerve.
These lesions have a different surgical and neuro-ophthalmic context.
Epidemiology
ONSM is uncommon.
It accounts for approximately:
- 1–2% of meningiomas
- A small proportion of orbital tumors
Most cases are:
- Unilateral
- Sporadic
Typical age at diagnosis:
Middle adulthood
with a female predominance.
Pediatric ONSM
ONSM is uncommon in children.
When diagnosed in a child or young adult, consider:
NF2-related schwannomatosis
formerly called neurofibromatosis type 2.
Pediatric ONSM may be:
- Bilateral
- Multifocal
- More strongly associated with an underlying tumor-predisposition syndrome
Genetics
Most sporadic ONSMs are not inherited.
Meningiomas frequently show alterations involving:
Chromosome 22 and the NF2 gene
When associated with NF2-related schwannomatosis, inheritance is:
Autosomal dominant
although de novo variants are common.
Pathophysiology
The tumor grows circumferentially around the optic nerve within its meningeal sheath.
Visual loss results from:
- Chronic axonal compression
- Ischemia of the optic nerve
- Disturbance of pial circulation
- Secondary venous outflow obstruction
Because the tumor often encases rather than directly invades the optic nerve, modern radiotherapy can control growth while preserving useful vision in many patients.
Clinical Presentation
The most common symptom is:
Slowly progressive painless visual loss
usually occurring over:
- Months
- Years
Other symptoms may include:
- Dyschromatopsia
- Visual field loss
- Relative afferent pupillary defect
- Proptosis
- Diplopia
- Transient visual obscurations
Visual Acuity
Visual acuity may range from:
- Normal or near-normal early
- Mildly reduced
- Profoundly reduced in advanced disease
Visual field and color vision abnormalities may precede major acuity loss.
Color Vision
Color vision is frequently reduced early because of:
Optic nerve dysfunction
and may be disproportionately impaired relative to Snellen acuity.
Relative Afferent Pupillary Defect
A RAPD is expected when disease is:
- Unilateral
- Markedly asymmetric
unless optic nerve function is profoundly reduced bilaterally.
Visual Field Defects
Possible field defects include:
- Central scotoma
- Cecocentral scotoma
- Arcuate defects
- Altitudinal defects
- Peripheral constriction
There is no single pathognomonic field pattern.
Serial perimetry is particularly useful for:
Monitoring progression.
Optic Disc Appearance
The optic disc may be:
- Normal
- Edematous
- Pale
- Atrophic
depending on:
- Tumor location
- Duration
- Degree of axonal damage
Optic Disc Edema
More anterior tumors may cause:
- Disc edema
- Venous congestion
because compression occurs closer to the globe.
Optic Atrophy
Posterior or chronic lesions more often produce:
Optic disc pallor
with corresponding:
- RNFL thinning
- Ganglion cell loss
Optociliary Shunt Vessels
A classic finding is:
Optociliary shunt vessels
These are collateral vessels on the optic disc connecting:
- Retinal venous circulation
- Choroidal circulation
They develop because chronic optic nerve sheath compression impairs normal venous drainage.
Classic Triad
The historical triad is:
- Progressive visual loss
- Optic atrophy
- Optociliary shunt vessels
This combination is highly suggestive of ONSM but:
Not pathognomonic.
Proptosis
Proptosis may occur when the tumor becomes sufficiently large within the orbit.
It is typically:
- Axial
- Slowly progressive
because the optic nerve occupies the intraconal space.
Ocular Motility
Diplopia or motility restriction may occur because of:
- Mass effect
- Mechanical displacement
- Advanced orbital involvement
but is usually not an early feature.
Diagnosis
Diagnosis is usually based on:
- Characteristic neuro-ophthalmic findings
- High-quality orbital MRI
Biopsy is generally unnecessary.
MRI – Investigation of Choice
The preferred imaging study is:
MRI of the brain and orbits with and without contrast
using:
- Thin orbital sections
- Fat-suppressed postcontrast T1 imaging
- Axial and coronal views
Characteristic MRI Findings
Typical findings include:
- Tubular enlargement around optic nerve
- Fusiform sheath enlargement
- Intense enhancement of the tumor
- Relative nonenhancement of the central optic nerve
This produces the classic:
Tram-track sign
on axial imaging.
Doughnut Sign
On coronal imaging, enhancing tumor surrounding the relatively less enhancing optic nerve may produce a:
Doughnut sign
or ring-like appearance.
Imaging Morphology
ONSM may appear:
- Tubular
- Fusiform
- Globular
- Focal
Tumor may extend through:
- Optic canal
- Orbital apex
and occasionally intracranially.
CT
Thin-section CT is particularly useful for detecting:
- Calcification
- Optic canal enlargement
- Hyperostosis
Calcification strongly supports a meningioma in the appropriate clinical setting.
MRI remains superior for:
- Soft tissue
- Optic nerve
- Intracranial extension
OCT
OCT is increasingly valuable for monitoring ONSM.
Assess:
- Peripapillary RNFL
- Macular ganglion cell complex / GCIPL
Progressive thinning reflects:
Axonal loss
and may help quantify chronic optic neuropathy.
Important OCT Principle
Severe preexisting:
- RNFL thinning
- GCIPL loss
suggests limited potential for visual recovery even if the tumor is successfully controlled.
Radiotherapy primarily aims to:
Preserve remaining function
rather than regenerate lost axons.
Visual Fields
Formal automated perimetry should be performed serially when vision permits.
It is useful for:
- Baseline documentation
- Detecting progression
- Assessing response after treatment
Biopsy
Biopsy is:
Rarely indicated
because characteristic MRI findings are usually sufficient and surgery around the optic nerve carries substantial visual risk.
When Biopsy May Be Considered
Biopsy may be considered when:
- Imaging is atypical
- Rapid progression suggests another disease
- Malignancy is suspected
- Inflammatory/infiltrative disease cannot be excluded
Even then, biopsy should be approached cautiously.
Why Biopsy Is Avoided
The optic nerve blood supply is intimately associated with:
- Meningeal vessels
- Pial vessels
- Tumor sheath
Surgical manipulation can cause:
- Ischemia
- Direct optic nerve injury
with permanent loss of vision.
Differential Diagnosis
Important differentials include:
- Optic pathway glioma
- Optic perineuritis
- Sarcoidosis
- Lymphoma
- Metastatic disease
- IgG4-related orbital disease
- Idiopathic orbital inflammation
- Optic neuritis
- Leukemic infiltration
- Other orbital tumors
ONSM vs Optic Nerve Glioma
ONSM
Typically:
- Middle-aged adult
- Female predominance
- Sheath enhancement around nerve
- Tram-track appearance
- Calcification possible
- Optociliary shunt vessels possible
Optic Pathway Glioma
Typically:
- Childhood
- NF1 association
- Fusiform enlargement of the optic nerve itself
- Less characteristic sheath-type enhancement
ONSM vs Optic Perineuritis
Optic perineuritis may also produce:
- Perineural enhancement
- Tram-track appearance
but usually has a different clinical setting.
Features favoring perineuritis include:
- More acute/subacute symptoms
- Orbital pain
- Inflammatory disease
- Steroid responsiveness
ONSM usually causes:
Slow, painless progression.
ONSM vs Optic Neuritis
Typical optic neuritis usually causes:
- Acute/subacute visual loss
- Pain with eye movement
- Dyschromatopsia
- Often younger age
- Intraneural rather than sheath-predominant enhancement
ONSM generally progresses much more slowly.
ONSM vs Sarcoidosis
Sarcoidosis may produce:
- Optic nerve sheath enhancement
- Optic neuropathy
- Orbital inflammation
Look for:
- Uveitis
- Lacrimal gland enlargement
- Systemic pulmonary findings
- Other inflammatory manifestations
Natural History
ONSM is usually:
Slow-growing
but progressive visual loss may occur even when tumor size changes little.
This reflects:
- Optic nerve compression
- Ischemic injury
rather than simply tumor volume.
Observation
Observation may be appropriate when:
- Vision is good
- Visual fields are stable
- Tumor is radiographically stable
- Patient is minimally symptomatic
This is especially reasonable in:
- Older patients
- Patients with significant medical comorbidity
Monitoring During Observation
Follow with:
- Visual acuity
- Color vision
- Pupils
- Visual fields
- OCT RNFL/GCIPL
- MRI
Initially, review may be every:
3–6 months
depending on disease severity.
MRI may be repeated approximately:
Every 6–12 months initially
then less frequently if stable.
Indications for Treatment
Treatment is considered when there is:
- Documented progressive visual loss
- Progressive visual field loss
- Tumor growth
- Significant visual impairment at presentation with salvageable vision
- Intracranial progression threatening the chiasm or fellow optic nerve
First-Line Definitive Treatment
For a patient with useful vision and progressive ONSM, the preferred treatment is:
Fractionated conformal radiotherapy
including modern:
- Fractionated stereotactic radiotherapy
- Intensity-modulated radiotherapy
- Proton therapy in selected centers
Why Fractionation Is Preferred
The optic nerve is highly sensitive to radiation injury.
Fractionating the total dose allows:
- Tumor control
- Better preservation of surrounding neural tissue
- Lower risk of radiation optic neuropathy than high single-dose treatment
Typical Radiation Dose
Common modern regimens use approximately:
50–54 Gy
delivered in fractions of roughly:
1.8 Gy
The exact regimen is determined by:
- Tumor geometry
- Prior radiation
- Optic nerve/chiasm constraints
- Radiation oncology planning
Treatment Outcomes
Fractionated radiotherapy achieves:
- Tumor control in >90% of cases
- Stabilization or improvement of vision in a large majority of appropriately selected patients
Visual recovery is more likely when treatment occurs before:
- Severe optic atrophy
- Profound RNFL loss
- Long-standing blindness
Time Course After Radiotherapy
Tumor size may not dramatically decrease.
Successful treatment is often reflected by:
- Stabilization of vision
- Improved visual field
- Reduced tumor growth
- Long-term radiographic stability
Therefore:
Clinical function is as important as tumor size.
Stereotactic Radiosurgery
Single-fraction stereotactic radiosurgery is generally less favored for tumors immediately surrounding a functional optic nerve because:
High single-dose radiation increases the risk of radiation optic neuropathy.
Fractionated techniques are usually preferred.
Surgery
Surgical excision of a primary ONSM is usually:
Avoided when useful vision remains.
Because the tumor surrounds and shares blood supply with the optic nerve, complete removal often results in:
Blindness in the operated eye.
Surgical Indications
Surgery may be considered when:
- Eye is already blind
- Tumor produces disfiguring or painful proptosis
- There is aggressive intracranial extension
- Diagnosis remains uncertain and tissue is essential
Even then, management should be individualized.
Intracranial Extension
Tumor extending toward:
- Optic canal
- Chiasm
- Contralateral optic nerve
requires multidisciplinary management involving:
- Neuro-ophthalmology
- Neurosurgery
- Radiation oncology
The priority is preventing:
Contralateral visual loss
and intracranial progression.
Pediatric Management
Treatment in children requires particular caution because of:
- Long life expectancy
- Radiation-related secondary tumor risk
- Endocrine and neurocognitive effects of cranial irradiation
Association with NF2-related schwannomatosis should be investigated in appropriate cases.
Radiation Complications
Possible complications include:
- Radiation optic neuropathy
- Radiation retinopathy
- Retinal vascular occlusion
- Cataract
- Dry eye
- Pituitary dysfunction depending on radiation field
- Secondary neoplasm, particularly relevant in younger patients
With modern fractionated techniques, severe complications are uncommon but not absent.
Radiation Retinopathy
Radiation retinopathy may develop:
- Months to years after treatment
Findings may include:
- Microaneurysms
- Hemorrhages
- Cotton-wool spots
- Macular edema
- Neovascularization
Treatment may include:
Intravitreal anti-VEGF
when macular edema or proliferative changes develop.
Radiation Optic Neuropathy
Radiation optic neuropathy causes:
- Sudden or subacute visual loss
- RAPD
- Optic disc edema or later pallor
Prevention through:
Appropriate radiation dose constraints
is critical because established injury can be severe and difficult to reverse.
Follow-Up After Treatment
Continue long-term monitoring with:
- Visual acuity
- Color vision
- Visual fields
- OCT RNFL/GCIPL
- MRI
Follow-up is required for years because:
- Tumor recurrence/progression can occur
- Radiation complications may be delayed
Prognosis
ONSM is histologically benign but can be:
Functionally devastating
because progressive compression may ultimately destroy the optic nerve.
Untreated progressive disease can lead to:
- Severe visual field loss
- Optic atrophy
- Blindness
Visual Prognosis
The best predictors of useful visual outcome include:
- Better vision at treatment
- Less severe optic atrophy
- Preserved RNFL/GCC
- Shorter duration of progressive visual loss
Once profound optic atrophy is established:
Visual recovery is unlikely.
Tumor Prognosis
Local tumor control after modern fractionated radiotherapy is:
Excellent
in most patients.
The main therapeutic goal is therefore:
Preservation of useful vision rather than eradication of a benign tumor at the cost of optic nerve function.
Complications
Potential complications of untreated ONSM include:
- Progressive compressive optic neuropathy
- Optic atrophy
- Severe visual field loss
- Blindness
- Proptosis
- Intracranial extension
Treatment complications include:
- Radiation retinopathy
- Radiation optic neuropathy
- Cataract
- Surgical blindness
Ophthalmology Pearls
- Optic nerve sheath meningioma is a usually benign tumor arising from arachnoid cap cells surrounding the optic nerve and causing chronic compressive optic neuropathy.
- The classic patient is a middle-aged woman with slowly progressive, painless, unilateral visual loss.
- The classic triad is progressive visual loss + optic atrophy + optociliary shunt vessels, although the full triad is not always present.
- MRI of the orbits with fat-suppressed postcontrast imaging is the diagnostic study of choice.
- The characteristic axial imaging appearance is the tram-track sign; coronal imaging may show a doughnut sign.
- CT is useful for demonstrating calcification and hyperostosis.
- OCT RNFL and GCIPL help quantify optic nerve damage and monitor progression.
- Biopsy is rarely required and may sacrifice vision, so characteristic radiographic cases are generally diagnosed noninvasively.
- Important mimics include optic glioma and optic perineuritis.
- Observation is appropriate when vision and imaging are stable.
- Progressive visual dysfunction with useful remaining vision is best treated with fractionated radiotherapy, typically around 50–54 Gy in conventional small fractions.
- Modern fractionated radiotherapy provides excellent local control and stabilizes or improves vision in most appropriately selected patients.
- Single-fraction radiosurgery is generally avoided near a functioning optic nerve because of the risk of radiation optic neuropathy.
- Surgical resection is usually avoided when useful vision remains, because removing the sheath tumor commonly damages or devascularizes the optic nerve.
- ONSM in children or young adults should raise consideration of NF2-related schwannomatosis.
- The key therapeutic principle is preserve remaining optic nerve function rather than aggressively excise a histologically benign tumor.
